^
    1d
    KEYNOTE-A72: A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=169, Completed, Astellas Pharma Global Development, Inc. | Phase classification: P1b --> P1
    Phase classification
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • ASP8374
    over2years
    KEYNOTE KN-A72: A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b, N=169, Completed, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • ASP8374
    3years
    KEYNOTE KN-A72: A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b, N=169, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Aug 2021 --> Mar 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • ASP8374
    almost4years
    KEYNOTE KN-A72: A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b, N=169, Active, not recruiting, Astellas Pharma Global Development, Inc. | N=300 --> 169 | Trial completion date: Feb 2023 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Aug 2021
    Clinical • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • ASP8374
    4years
    KEYNOTE KN-A72: A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b, N=300, Active, not recruiting, Astellas Pharma Global Development, Inc. | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed • Combination therapy • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • ASP8374
    over4years
    KEYNOTE KN-A72: A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1b, N=300, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Apr 2022 --> Feb 2023 | Trial primary completion date: Jul 2021 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • ASP8374
    over4years
    Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Completed, Astellas Pharma Inc | Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jun 2020 | Trial primary completion date: Dec 2022 --> Jun 2020
    Clinical • Trial completion • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    ASP8374
    almost5years
    Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Astellas Pharma Inc | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    ASP8374